Large MiRNA Survival Analysis Reveals a Prognostic Four-biomarker Signature for Triple Negative Breast Cancer

Overview

Journal Genet Mol Biol

Specialty Genetics

Date 2019 Sep 6

PMID 31487369

Citations 11

Authors

Fernando Andrade

Asuka Nakata

Noriko Gotoh

Andre Fujita

Affiliations

Soon will be listed here.

Abstract

Triple negative breast cancer (TNBC) is currently the only major breast tumor subtype without effective targeted therapy and, as a consequence, usually presents a poor outcome. Due to its more aggressive phenotype, there is an urgent clinical need to identify novel biomarkers that discriminate individuals with poor prognosis. We hypothesize that miRNAs can be used to this end because they are involved in the initiation and progression of tumors by altering the expression of their target genes. To identify a prognostic biomarker in TNBC, we analyzed the miRNA expression of a cohort composed of 185 patients diagnosed with TNBC using penalized Cox regression models. We identified a four-biomarker signature based on miR-221, miR-1305, miR-4708, and RMDN2 expression levels that allowed for the subdivision of TNBC into high- or low-risk groups (Hazard Ratio - HR = 0.32; 95% Confidence Interval - CI = 0.11-0.91; p = 0.03) and are also statistically associated with survival outcome in subgroups of postmenopausal status (HR = 0.19; 95% CI = 0.04-0.90; p= 0.016), node negative status (HR = 0.12; 95% CI = 0.01-1.04; p = 0.026), and tumors larger than 2cm (HR = 0.21; 95% CI = 0.05-0.81; p = 0.021). This four-biomarker signature was significantly associated with TNBC as an independent prognostic factor for survival.

Citing Articles

The miR-1305/KLF5 negative regulatory loop affects pancreatic cancer cell proliferation and apoptosis.

Zhou Y, Tang Y, Huang F, Wang Z, Wen Z, Fang Q Hum Cell. 2025; 38(2):51.

PMID: 39921786 DOI: 10.1007/s13577-025-01173-3.

Construction of a novel radioresistance-related signature for prediction of prognosis, immune microenvironment and anti-tumour drug sensitivity in non-small cell lung cancer.

Chen Y, Zhou C, Zhang X, Chen M, Wang M, Zhang L Ann Med. 2025; 57(1):2447930.

PMID: 39797413 PMC: 11727174. DOI: 10.1080/07853890.2024.2447930.

Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches.

Pastena P, Perera H, Martinino A, Kartsonis W, Giovinazzo F Int J Mol Sci. 2024; 25(5).

PMID: 38473804 PMC: 10931553. DOI: 10.3390/ijms25052559.

Modulatory role of miRNAs in thyroid and breast cancer progression and insights into their therapeutic manipulation.

Ahmed R, Samanta S, Banerjee J, Kar S, Dash S Curr Res Pharmacol Drug Discov. 2022; 3:100131.

PMID: 36568259 PMC: 9780070. DOI: 10.1016/j.crphar.2022.100131.

Oncoinformatic screening of the gene clusters involved in the HER2-positive breast cancer formation along with the in silico pharmacodynamic profiling of selective long-chain omega-3 fatty acids as the metastatic antagonists.

Morshed A, Azad S, Mia M, Uddin M, Ema T, Yeasin R Mol Divers. 2022; 27(6):2651-2672.

PMID: 36445532 DOI: 10.1007/s11030-022-10573-8.

References

Tormo E, Pineda B, Serna E, Guijarro A, Ribas G, Fores J . MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer. J Cell Biochem. 2015; 116(9):2061-73. DOI: 10.1002/jcb.25162. View

Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L . Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3):719-26. DOI: 10.1200/JCO.2002.20.3.719. View

Helms M, Packeisen J, August C, Schittek B, Boecker W, Brandt B . First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. J Pathol. 2005; 206(3):366-76. DOI: 10.1002/path.1785. View

Lowery A, Miller N, Devaney A, McNeill R, Davoren P, Lemetre C . MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009; 11(3):R27. PMC: 2716495. DOI: 10.1186/bcr2257. View

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

Schutte M, Hruban R, Hedrick L, Cho K, Nadasdy G, Weinstein C . DPC4 gene in various tumor types. Cancer Res. 1996; 56(11):2527-30. View

Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K . MicroRNAs modulate the angiogenic properties of HUVECs. Blood. 2006; 108(9):3068-71. DOI: 10.1182/blood-2006-01-012369. View

Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K . Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003; 9(11):1370-6. DOI: 10.1038/nm948. View

Kayed H, Jiang X, Keleg S, Jesnowski R, Giese T, Berger M . Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer. Br J Cancer. 2007; 97(8):1106-15. PMC: 2360444. DOI: 10.1038/sj.bjc.6603984. View

10.

Zeiher A . Endothelial vasodilator dysfunction: pathogenetic link to myocardial ischaemia or epiphenomenon?. Lancet. 1996; 348 Suppl 1:s10-2. DOI: 10.1016/s0140-6736(96)98004-6. View

11.

le Sage C, Nagel R, Egan D, Schrier M, Mesman E, Mangiola A . Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007; 26(15):3699-708. PMC: 1949005. DOI: 10.1038/sj.emboj.7601790. View

12.

Zeng Y, Yi R, Cullen B . MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A. 2003; 100(17):9779-84. PMC: 187842. DOI: 10.1073/pnas.1630797100. View

13.

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

14.

Besson A, Hwang H, Cicero S, Donovan S, Gurian-West M, Johnson D . Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev. 2007; 21(14):1731-46. PMC: 1920168. DOI: 10.1101/gad.1556607. View

15.

Deckers M, van Dinther M, Buijs J, Que I, Lowik C, van der Pluijm G . The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006; 66(4):2202-9. DOI: 10.1158/0008-5472.CAN-05-3560. View

16.

Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K . Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer. 2009; 17(2):118-24. DOI: 10.1007/s12282-009-0113-0. View

17.

Levy L, Hill C . Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol. 2005; 25(18):8108-25. PMC: 1234333. DOI: 10.1128/MCB.25.18.8108-8125.2005. View

18.

Oishi K, Okano H, Sawa H . RMD-1, a novel microtubule-associated protein, functions in chromosome segregation in Caenorhabditis elegans. J Cell Biol. 2007; 179(6):1149-62. PMC: 2140014. DOI: 10.1083/jcb.200705108. View

19.

Chen Z, Liu H . Restoration of miR-1305 relieves the inhibitory effect of nicotine on periodontal ligament-derived stem cell proliferation, migration, and osteogenic differentiation. J Oral Pathol Med. 2016; 46(4):313-320. DOI: 10.1111/jop.12492. View

20.

Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V . MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007; 14(3):791-8. DOI: 10.1677/ERC-07-0129. View